Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

Allergic Rhinitis Clinical Trial

Official title:

National, Multicenter, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05684380
• Other study ID #: EMS0422 - AZALEIA
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: September 2024
• Est. completion date: May 2025

Study information

• Verified date: February 2024
• Source: EMS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of MAZ-101 in the treatment of moderate-severe persistent allergic rhinitis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 514
• Est. completion date: May 2025
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Participants of both sexes, with age greater than or equal to 12 years;
• Clinical diagnosis of moderate-severe persistent for at least 1 year;
• Screening Visit: A 12-hour reflective TNSS = 8 out of a possible 12 and a congestion score of 2 or 3;
• Randomization Visit: A 12-hour reflective TNSS (AM or PM) = 8 on 3 separate symptoms assessments during the Lead-in Period; an AM or PM 12-hour reflective nasal congestion score of 2 or 3 must have been recorded on 3 separate symptom assessments;
• Present skin sensitization test to at least one aeroallergen.

Exclusion Criteria:

• Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
• Other clinical forms of rhinitis;
• Subjects receiving immunotherapy;
• Presence of nasal polyposis;
• Patients with severe arterial hypertension, severe coronary diseases, cardiac arrhythmias, glaucoma, ocular herpes simplex, cataracts, hyperthyroidism;
• Asthma sufferers; respiratory tract infections and lung disease, including chronic obstructive pulmonary disease (COPD);
• Presence of grade II or III septal deviation and/or presence of nasal polyps or other conditions that determine nasal obstruction;
• Concomitant chronic or intermittent use of decongestants and/or antihistamines and/or inhaled, oral, intramuscular, intravenous or potent topical corticosteroids;
• Participants using monoamine oxidase inhibitors (MAOIs);
• Participants with known allergy or hypersensitivity to the components of the drugs used during the clinical trial;
• History of alcohol abuse or illicit drug use;
• Pregnancy or risk of pregnancy and lactating patients;

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic

Intervention

Drug:
• MAZ-101association
Experimental drug
• DYMISTA®
Active comparator

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
EMS

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in AM+PM rTNSS (reflective total nasal symptoms score).	Change from baseline in 12-hour reflective total nasal symptom score (rTNSS) consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary for the entire 28 day study period. The measurement scale is 0 to 24 so that the higher the number the worse the symptom.	28 days.
Secondary	Change from baseline in AM+PM rTOSS (reflective total ocular symptom score).	Change from baseline in 12-hour reflective total ocular symptom score (rTOSS) consisting of itching/burning, tearing/watering, and redness scored twice daily (AM and PM) in diary for the entire 28 day study period. The measurement scale is 0 to 18 so that the higher the number the worse the symptom.	28 days.
Secondary	Change from baseline in AM + PM: rTNSS (reflective total nasal symptoms score) plus rTOSS (reflective total ocular symptom score).	Change from baseline in 12-hour rTNSS plus rTOSS consisting of nasal congestion,runny nose, itchy nose and sneezing that represents rTNSS and itching/burning, tearing/watering, and redness that represents rTOSS scored twice daily (AM and PM) in diary for the entire 28 day study period. The measurement scale is 0 to 24 of rTNSS plus 0 to 18 of rTOSS. Then, the (rTNSS plus rTOSS ) measurement scale is 0 to 42 so that the higher the number the worse the symptom.	28 days.
Secondary	Change from baseline in reflective individual nasal symptom scores.	Change from baseline in the 12-hour reflective individual nasal symptom scores consisting of nasal congestion,runny nose, itchy nose, sneezing scored twice daily (AM and PM) in diary for the entire 28 day study period. The measurement scale is 0 to 3 in each symptom so that the higher the number the worse the symptom.	28 days.
Secondary	Change from baseline in reflective individual ocular symptom scores.	Change from baseline in the 12-hour reflective individual ocular symptom scores consisting of itching/burning, tearing/watering, and redness scored twice daily (AM and PM) in diary for the entire 28 day study period. The measurement scale is 0 to 3 in each symptom so that the higher the number the worse the symptom.	28 days.
Secondary	Change from baseline in the Rhinoconjunctivitis Quality of Life Questionnaire for adults (RQLQ) or Rhinoconjunctivitis Quality of Life Questionnaire for adolescents (AdolRQLQ).	Change compared to baseline in the general score of the Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) or adolescent (AdoRQLQ) after 28 days os treatment. The RQLQ has 28 questions and the AdolRQLQ has 25 questions. Participants will respond to each question on a 7-point scale (0 = not at all impaired to 6 = severely impaired) according to how bothered the participants were by their rhinoconjunctivitis during the past week.	28 days.
Secondary	Number of days without nasal symptoms	Number of days without nasal symptoms (rTNSS = 0) for the entire 28-day study period.	28 days.